Zhao SG, et al. - In order to gain insights into the immune landscape in prostate cancer, researchers analyzed 9,393 samples, including 7,826 prospectively collected prostatectomy samples and 1,567 retrospective samples with long-term clinical outcomes. They also investigated immune-related biomarkers and possible targets for treatment. Analysis of gene expression data was performed. Worse biochemical recurrence-free survival, distant metastasis-free survival (DMFS), prostate cancer-specific survival, and overall survival were observed in relation to higher projected immune content scores based on immune-specific genes from the literature. Improved DMFS was offered by mast cells, natural killer cells, and dendritic cells. This was the largest study addressing this topic. The tumor-immune interaction, prognosis, and response to radiotherapy were correlated in a complex manner. PD-L2 could be a potential new target to treat prostate cancer, possibly combined with radiotherapy.